Vienna-based vaccine developer Themis signs pact with Merck for 'blockbuster indication'
Months after securing up to $21 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for its Chikungunya vaccine — which is being prepped for a late-stage trial — Vienna, Austria-based Themis Bioscience entered into a pact with US drugmaker Merck.
The European vaccine developer formed in 2009 and a year later joined forces with the Institut Pasteur — gaining exclusive access to a measles virus vaccine vector technology, which now forms the backbone of its platform.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters